Meridian Management’s ImmunityBio IBRX Stock Holding History

Meridian Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-10,000	Closed	-$63.2K	–	98
2024 Q2	$63.2K	Hold	10,000	–	–	0.02%	97
2024 Q1	$53.7K	Hold	10,000	–	–	0.01%	101
2023 Q4	$45.8K	Buy	+10,000	New	+$31.4K	0.01%	96

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Meridian Management's IBRX Position: Q3 2024 in Review

Meridian Management sold out of ImmunityBio (IBRX) in Q3 2024, closing a stake of 10,000 shares — an estimated $63.2K sold.

Meridian Management first reported a position in IBRX in Q4 2023 and held it in 3 quarters. The position peaked at $63.2K in Q2 2024. 181 funds tracked by Wall St. Rank hold IBRX as of Q3 2024.

Meridian Management reported no remaining ImmunityBio position as of Q3 2024 after selling out during the quarter.
Meridian Management sold 10,000 ImmunityBio shares in Q3 2024, an estimated $63.2K.
Meridian Management first reported a position in ImmunityBio in Q4 2023 and held it in 3 quarters.
Meridian Management's ImmunityBio position peaked at $63.2K in Q2 2024.
181 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2024.

Based on Meridian Management's 13F filing for Q3 2024, filed 4 Nov 2024.